FDA Reviews New Atopic Dermatitis Cream for Infants

The FDA has accepted Arcutis Biotherapeutics' application to expand the use of ZORYVE® cream 0.05% for treating mild to moderate atopic dermatitis in infants aged 3 to 24 months. This development could provide a much-needed steroid-free treatment option for a vulnerable young population. A decision from the FDA is anticipated by February 23, 2027.